版本:
中国

BRIEF-Auris Medical Holding AG provides update on its treatment for acute inner ear tinnitus

Oct 11 Auris Medical Holding AG :

* Auris Medical provides update on development of Keyzilen for the treatment of acute inner ear tinnitus

* based on insights from TACTT2 trial, submitting protocol amendment to regulatory agencies in Europe for TACTT3

* expects enrollment to resume in early 2017; top-line results from the expanded TACTT3 trial are now expected in early 2018

* says outcomes from TACTT2 and regulatory path forward will be reviewed with US FDA in early December 2016

* "disappointed that the TACTT2 trial failed to confirm the efficacy of keyzilen in the overall study population" Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐